Arcturus to receive upfront payment of $200 million and more than $4 billion in potential development and commercial milestones
40% profit sharing for COVID-19 vaccines, up to double digit royalties for influenza, pandemic preparedness and three additional respiratory infectious disease vaccines
Combines Arcturus’ self-amplifying mRNA vaccine technologies with CSL’s world-leading capabilities as a commercial scale manufacturer and global distributor of influenza and pandemic vaccines
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.